Suppressor of cytokine signaling (SOCS) proteins have emerged as critical attenuators of cytokine-mediated processes, suggesting a role in the suppression of tumorigenesis. In the ovary and mammary gland, cytokines such as prolactin and IL-6 are important regulators of growth and differentiation. We have investigated whether silencing or inactivation of SOCS genes occurs in ovarian and breast carcinomas. The SOCS1 and SOCS2 CpG islands were found to be hypermethylated in 23 and 14% of primary ovarian cancers, respectively, whereas only SOCS1 was methylated in breast cancers (9%). Methylation of these genes did not occur in normal tissues. No correlation was apparent between methylation and loss of heterozygosity, and no somatic mutations were found in a large panel of carcinomas. Aberrant methylation of these SOCS genes correlated with transcriptional silencing in ovarian and breast cancer cell lines, since expression was induced by the demethylating agent 5-azadeoxycytidine. SOCS3 was not hypermethylated in either cancer type. Consistent with this data, SOCS1 and SOCS2 but not SOCS3 suppressed the growth of ovarian and breast cancer cells. Hypermethylation and silencing of specific SOCS genes in the ovary, and to a lesser extent in breast, may augment cytokine responsiveness in these tissues, thereby contributing to oncogenesis.
Suppressors of cytokine signaling (SOCS) proteins have emerged as critical regulators of cytokine-mediated signaling in diverse tissues. These proteins act in a negative feedback loop to attenuate signaling via the Janus kinase-Signal transducers and activators of transcription (JAK-Stat) pathway (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997) . The eight members of this family (SOCS1-SOCS7 and CIS) are characterized by an amino-terminal region of limited homology, a central SH2 domain and a conserved SOCS box at the C-terminus. SOCS proteins interact with cytokine receptors and/or Janus kinases through their SH2 domain, leading to inhibition of kinase activity and consequent lack of Stat activation (Narazaki et al., 1998; Yasukawa et al., 1999) . These proteins also target the signaling proteins to which they bind for ubiquitination and proteasomal degradation, thereby contributing to the tight regulation of cytokine signaling (Ram and Waxman, 2000; Kamizono et al., 2001) .
Several members of the SOCS family have been implicated as negative regulators of the prolactin (Prl) pathway in mammary epithelium and the ovary. Expression of the SOCS1, SOCS2, SOCS3 and CIS genes is induced by Prl in mammary epithelial cells and in the mammary gland (Pezet et al., 1999; Tam et al., 2001) . Within the ovary, SOCS genes are also differentially induced by Prl and may provide an inhibitory feedback response to physiological Prl surges in luteal and other ovarian cells during lactation (Tam et al., 2001) . SOCS proteins have been demonstrated to act as potent inhibitors of Prl signaling in different cellular systems in vitro (Helman et al., 1998; Pezet et al., 1999; Tomic et al., 1999; Lindeman et al., 2001) and we have established a physiological role for SOCS1 as a negative regulator of the prolactin pathway in the mammary gland (Lindeman et al., 2001) . Targeted deletion of Prl and its receptor (PrlR) has revealed that these genes play an essential role in mammary and ovarian development and in the maintenance of pregnancy (Horseman et al., 1997; Ormandy et al., 1997; Grosdemouge et al., 2003) . Other cytokines, including growth hormone and IL-6, which are also regulated by SOCS proteins, appear to exert key functions in these organs. Growth hormone is required for mammary ductal proliferation and branching (Silberstein and Daniel, 1987) and promotes the growth of breast cancer cell lines via an autocrine/ paracrine mechanism (Kaulsay et al., 1999) . IL-6 deficiency leads to delayed involution in the mammary gland (Zhao et al., 2002) and participates in follicle development in the ovary (Machelon et al., 1994) . Further, increased serum levels of IL-6 have been observed in ovarian cancer patients (Nash et al., 1999 ). SOCS1 appears to be an important tumor suppressor in specific cancers. The SOCS1 gene is frequently silenced by promoter hypermethylation in hepatocellular carcinoma (65%), providing the first evidence for the involvement of this gene in oncogenesis (Yoshikawa et al., 2001) . Most recently, SOCS1 has also been shown to be hypermethylated in multiple myelomas (62%) (Galm et al., 2003) , in a subset of acute myeloid leukemias (60%) (Chen et al., 2003) and in pancreatic ductal neoplasms (21%) (Fukushima et al., 2003) . These findings indicate the importance of constitutive activation of the Jak/Stat pathway in the pathogenesis of different cancers.
We have explored a role for SOCS genes as potential tumor suppressors in ovarian and breast carcinomas, given that they are important attenuators of Prl, growth hormone and IL-6-mediated signal transduction and that SOCS1 has been reported to be silenced in carcinomas. We have performed a comprehensive analysis of three members of the SOCS gene family (SOCS1-3) by addressing methylation-associated silencing, allelic loss and the presence of somatic mutations in a large panel of primary ovarian and breast cancers. Here we provide evidence that aberrant methylation of specific SOCS genes occurs in these cancers. Both the SOCS1 and SOCS2 genes were aberrantly methylated in ovarian carcinomas, while only SOCS1 was hypermethylated in breast tumors. SOCS3 was not found to be hypermethylated in either cancer. Neither LOH nor the acquisition of somatic mutations appeared to play a major role in SOCS gene inactivation. Our findings suggest that hypermethylation of SOCS genes in ovarian cancers and a proportion of breast cancers leads to gene silencing which in turn may elicit increased epithelial proliferation and/or survival in response to cytokines.
To assess the level of SOCS1-3 transcripts in ovarian cancer cell lines, we used real-time PCR, since expression of the SOCS1 and SOCS2 genes was found to be very low by Northern analysis (data not shown). Values were normalized against S14 ribosomal RNA levels in the same sample. SOCS1 expression was negligible in all the ovarian cell lines (Figure 1a) . Although SOCS2 transcript levels were very low in the majority of cell lines examined, they were moderately abundant in OVCA-432 cells. Conversely, moderate to high levels of SOCS3 transcripts were evident in all cell lines, particularly in OVCA-432 and OVHS-1 cells. In the immortalized ovarian cells HOSE and DOVE, SOCS1 and SOCS2 mRNA levels were found to be very low and equivalent to that observed in cancer cell lines (data not shown), while SOCS3 mRNA expression was negligible. The low or undetectable expression of SOCS1 and SOCS2 in many ovarian carcinoma lines further suggested that these genes may undergo silencing or mutagenesis in ovarian cancers.
The SOCS1, SOCS2 and SOCS3 genes are abundantly expressed in the ductal and alveolar epithelia of the developing mouse mammary gland (Helman et al., 1998; Pezet et al., 1999; Tomic et al., 1999; Lindeman et al., 2001) . To determine whether loss of SOCS gene expression occurs in neoplastic cells, we initially examined the expression of these genes in human breast cancer cell lines. Northern analysis revealed that SOCS1 expression was detectable but low in several cell lines including the immortalized human breast epithelial cells 184, whereas higher levels were present in mouse mammary epithelial cells SCp2 (Figure 1b) . In contrast, SOCS2 and SOCS3 RNA levels were found to be relatively abundant in several cell lines. However, low or undetectable levels of SOCS2 transcripts were evident in MCF-7, T-47D, BT-549, ZR-75B and PMC42 cell lines, and low SOCS3 mRNA expression was observed in 184, MCF-7, T-47D, SK-BR-3, BT-474, ZR-75B and þ RNA (2 mg), isolated from human breast cancer and mouse mammary epithelial cell lines (SCp2). Filters were hybridized sequentially with mouse SOCS probes followed by a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe PMC42 cells. These data suggested that silencing of SOCS genes might occur during transformation of breast epithelium.
As tumor suppressor genes frequently acquire somatic mutations that lead to gene inactivation or alteration of function, we screened the SOCS1, SOCS2 and SOCS3 genes for the presence of somatic mutations. We examined 50 primary ovarian carcinomas, 68 primary breast and 17 tumor cell lines using denaturing highperformance liquid chromatography (DHPLC) (Xiao and Oefner, 2001) . Primers (sequences available on request) were designed to amplify overlapping PCR products that spanned the entire coding regions and included the intron-exon boundaries of the SOCS1, SOCS2 and SOCS3 genes. No aberrant DHPLC peaks were detected in SOCS2 or SOCS3 in any of the primary cancers or cancer cell lines. An aberrant peak was observed in exon 2 of SOCS1 in three (4.4%) primary breast carcinomas (BC-1040, BC-1060 and BC-1084) and one ovarian tumor cell line, SKOV3. Direct sequencing of PCR products revealed a G to C transition resulting in a nonconservative amino-acid substitution of Glu for His (Glu209His) in the C-terminal SOCS box of the SOCS1 gene. Analysis of the matching normal DNA showed that this was a germline variant. To assess the possibility that this represents a breast cancer predisposing allele, we analysed lymphocyte DNA from 139 noncancer control subjects drawn from the same population as the cases. Four control subjects (3%) carried the same amino-acid substitution, indicating that this variant is likely to be a polymorphism of no pathological significance. However, this does not exclude the possibility that the nonconservative mutation may modulate the function of the SOCS box.
To determine whether aberrant methylation of CpG islands and silencing of SOCS genes occurred in primary ovarian and breast cancers, we initially determined the methylation status of the SOCS1, SOCS2 and SOCS3 genes in cell lines using MS-SSCP analysis (Dobrovic et al., 2002; Guilleret et al., 2002) . We selected MS-SSCP as the primary method for detection since this is an unbiased technique allowing identification of both methylated and unmethylated allele mixtures in the same sample. The SSCP method is very sensitive and alleles representing only 5% of the total DNA are still easily detected (Chaubert et al., 1993) . This contrasts with MSP, used in previous SOCS methylation studies (Yoshikawa et al., 2001; Chen et al., 2003; Fukushima et al., 2003) , which uses primers specific for either methylated or unmethylated DNA and is not quantitative. We found that SOCS1 was hypermethylated in 4/6 ovarian carcinoma cell lines and in 8/11 of breast cancer cell lines (Table 1) , a subset of which is shown in Figure 2a . The band shifts observed with the methylated alleles are variable indicating a spectrum of methylation. We next examined the methylation status and expression of SOCS1 in primary ovarian and breast cancers. The SOCS1 CpG islands were hypermethylated in 10/43 (23%) ovarian and 4/43 (9%) breast cancers (Figures 2b and c). Matched DNA derived from nontumor tissue (N) adjacent to the ovarian or breast tumor was analysed for each cancer that exhibited SOCS gene methylation, but no methylation was detectable in any of these tissues (Figure 2b ). We subsequently examined SOCS1 expression in several ovarian tumor samples using real-time PCR and found that those exhibiting SOCS1 hypermethylation contained significantly lower levels of SOCS1 mRNA (Figure 2b) .
To address the pattern of methylation across the 57 CpG sites in the 5 0 region of the SOCS1 gene, we used bisulfite sequencing for analysis of DNA from several cell lines and primary ovarian tumors (Figure 2d ). Ovarian carcinomas and breast cancer cell lines (MDA-MB-231, T-47D) displaying methylated SOCS1 by MS-SSCP were found to be densely methylated across the promoter region. In contrast, no methylation was detected in normal ovarian tissues (Figure 2d ). Sequencing of SssI methylase-treated normal samples demonstrated that bisulfite conversion was extremely efficient (Figure 2d ).
Silencing of genes by CpG island hypermethylation can be reversed by the demethylating agent 5-azadeoxycytidine (5-aza-dC). To explore the correlation between 
'+' indicates methylation and 'À' represents nonmethylation, results are derived from MS-SSCP analysis.
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The MS-SSCP indicated that a very minor proportion of the HBL-100 DNA was methylated, but since this was estimated to be less than 5%, this cell line has been designated as nonmethylated for SOCS1 methylation and SOCS1 gene expression, we treated ovarian (OVHS-1, JAM) and breast cancer (MDA-MB-435, MDA-MB-231, T-47D, HBL-100) cell lines with 5-aza-dC for 72 h and performed reverse transcription-PCR. In ovarian cancer cell lines, 5-aza-dC was found to restore SOCS1 expression in OVHS-1 cells (Figure 2e ). In contrast, no change in expression was observed in treated JAM cells, which contain nonmethylated SOCS1 alleles (Figure 2e ), thus providing a control. These observations were confirmed by real-time PCR where a 14-fold increase in SOCS1 mRNA expression was observed upon 5-aza-dC treatment of OVHS-1 cells (data not shown). In addition, 5-aza-dC treatment restored SOCS1 gene expression in MDA-MB-435, MDA-MB-231 and T-47D breast cancer cells but not in HBL-100 cells, which contain nonmethylated alleles (Figure 2e ). Figure 2 The SOCS1 CpG island is aberrantly methylated in ovarian and breast cell lines and primary carcinomas. (a) Genomic DNA was modified by sodium bisulfite as described (Dobrovic et al., 2002) . CpG islands were amplified using primers sets designed to amplify both bisulfite-modified methylated and unmethylated DNA, but not unmodified DNA, with no bias towards amplification of one particular product. Bisulfite-sequence analysis of DNA from breast cancer lines and ovarian carcinomas. Bisulfite-treated DNA was amplified using the MS-SSCP SOCS1 primer set (a). The PCR products were cloned into pCR2.1-Topo vector (Invitrogen), and 3-7 clones for each sample were sequenced. Filled and open squares represent methylated and unmethylated CpG islands, respectively. One out of six clones from each of the normal ovarian tissues contained a single methylated CpG, while 3/6 OC-70 clones displayed hypermethylation. (e) Reactivation of SOCS1 expression in ovarian and breast cell lines by 5-aza-dC treatment. Ovarian and breast cancer cell lines were cultured with ( þ ) or without (À) 5-aza-dC (Sigma) for 72 h. 5-Aza-dC at 5 or 2 mM was used for ovarian and breast cell lines, respectively. Total RNA was isolated from 5-aza-dC-treated cell lines using RNAzol (Tel-Test, Friendswood), and expression of SOCS1 was determined using reverse transcription-PCR analysis. S14 levels (primers as in Figure 1a ) provided a loading control. Sequences of the SOCS1 primers: forward 5 0 -ATGGTAGCACGCAACCAGGTG-3 0 and reverse 5 0 -CTCCAGCAGCTCGAAAAGGCA-3 0 . PCR products were fractionated by agarose gel electrophoresis, blotted onto Hybond N þ membranes and hybridized with internal oligonucleotide probes SOCS gene methylation in ovarian and breast cancer KD Sutherland et al Analysis of SOCS2 CpG island methylation in cell lines using MS-SSCP revealed that hypermethylation occurred in 4/6 ovarian and 8/10 breast cancer cell lines examined (Figure 3a) . In primary carcinomas, SOCS2 was found to be methylated in 6/42 (14%) ovarian (Figure 3b) but not in breast cancers (data not shown). Matched DNA derived from nontumor tissue adjacent to the breast or ovarian tumor was analysed for each cancer that exhibited SOCS gene methylation, but none was detectable in any of these tissues (Figure 3b) . We examined SOCS2 expression in several ovarian tumor samples using real-time PCR and found that those exhibiting gene hypermethylation (OC-43, OC-78) contained significantly lower levels of SOCS2 mRNA compared to unmethylated control samples (OC-47, OC-154) and normal tissue (370) (Figure 3b ). Bisulfitesequencing across 34 CpG islands in SOCS2 confirmed the results obtained from MS-SSCP analysis for ovarian cell lines (Figure 3c ). We did not observe any methylation of normal ovarian tissue (data not shown). Upon treatment of ovarian cancer cells with 5-aza-dC, increased SOCS2 expression was observed in PEO1 cells, whereas no difference was observed in JAM cells which contain nonmethylated SOCS2 alleles (Figure 3d ). In the breast cancer cell lines MDA-MB-435, MDA-MB-231 and HBL-100 cells, 5-aza-dC was found to induce SOCS2 expression.
Since loss of heterozygosity (LOH) can occur in combination with hypermethylation of the other allele, we investigated whether LOH provided another genetic mechanism by which to silence SOCS genes in primary breast or ovarian cancers. The primary ovarian and breast tumor samples were analysed for allelic loss using paired microsatellite DNA markers (available on request) that flank the SOCS1-3 gene loci. The ovarian carcinomas exhibited a higher frequency of LOH at all loci compared to the breast carcinomas, consistent with their characteristic propensity for genomic instability. The highest frequency of LOH in each tumor type was observed at the SOCS3 locus while the SOCS1 and SOCS2 loci exhibited a lower degree of LOH (Table 2) . Although the higher frequency of LOH at the 17q25.3 locus may reflect selective targeting of SOCS3, the absence of any methylation or somatic mutations in this gene suggests that the LOH reflects its proximity to the BRCA1 tumor suppressor locus. These data indicate that LOH is not a major mechanism underlying gene silencing in these carcinomas. There appeared to be no significant association between SOCS gene hypermethylation and LOH, although the sample numbers are small. For example, among the 10 ovarian cancers with SOCS1 methylation, 3/10 showed accompanying LOH of the other allele. To investigate whether overexpression of SOCS genes in ovarian PEO1 cells, in which both SOCS1 and SOCS2 are methylated, leads to growth inhibition, we generated stable transfectants expressing either SOCS1, SOCS2 or SOCS3. Following selection, the number of colonies for SOCS1 and SOCS2 transfectants was reduced by three-to fourfold compared with that observed in the vector control and SOCS3 transfectants (Figure 4a ). We have observed increased phospho-Stat3 in ovarian cell lines (PEO1 and OVHS-1) containing hypermethylated SOCS1 and SOCS2 genes, relative to cells in which these genes are not methylated (data not shown). Thus, SOCS gene methylation appears to be associated with gene silencing and increased Stat activity.
In addition, we examined suppression of colony growth by SOCS genes in MCF-7 breast cancer cells, in which both SOCS1 and SOCS2 appear to undergo methylation-associated silencing. MCF-7 cells carrying the ecotropic gp70 receptor were infected with retroviruses encoding Flag-tagged SOCS1, SOCS2 or SOCS3 and tested for their ability to grow in soft agar. Expression was confirmed by Western blotting using an anti-Flag monoclonal antibody (Figure 4b ). Both the SOCS1 and SOCS2 stable transductants exhibited a twofold decrease in the number of colonies compared to control cells harboring empty vector, when assayed for anchorage-independent growth (Figure 4b ). These data correlate with previous findings that SOCS1 suppresses growth of hepatocellular carcinoma cells (Yoshikawa et al., 2001 ) and inhibits proliferation induced by a number of oncogenes in hematopoietic cells (Rottapel et al., 2002) . However, an increase in RNA levels of SOCS1, SOCS2 and SOCS3 has recently been reported in tumor tissue and reactive stroma from breast cancer patients (Raccurt et al., 2003) .
Overexpression of SOCS3 in breast epithelial cells did not suppress colony growth, but conversely, led to a twofold increase in the number of colonies (Figure 4b) . Further, little difference in colony number was apparent in PEO1 ovarian cells (Figure 4a ). These data, together with the findings that the SOCS3 gene was not hypermethylated in 37 ovarian and 33 breast tumors and did not contain somatic mutations, indicate that SOCS3 is unlikely to have a tumor suppressor function in these tissues. In parallel, recent findings in other cellular systems suggest that SOCS3 may have a distinct role from SOCS1 in tumorigenesis. Constitutive expression of SOCS3 was found to occur in cutaneous T-cell lymphomas (Brender et al., 2001 ) and chronic myelogenous leukemia cells (Sakai et al., 2002) , in which it is likely to be mediated by constitutive activation of Stat3 (Brender et al., 2001) . In lung carcinomas, however, SOCS3 was recently found to be silenced by methylation (He et al., 2003) . Restoration of SOCS3 expression in lung cancer cells suppressed cell growth in vitro and led to a decrease in activated Stat3 levels. Thus, although SOCS3 may have different roles in different cancer types, deregulation of its expression appears to be associated with constitutive Stat3 activity, underscoring the importance of Stat3 in oncogenesis.
It has become increasingly clear that aberrant gene methylation and consequent gene silencing provide a selective advantage to neoplastic cells. CpG island hypermethylation of genes, including BRCA1 (Catteau and Morris, 2002) , p16
INK4a (Herman et al., 1996) , Ecadherin (Graff et al., 1995) and ERa (Ottaviano et al., 1994) , has been shown to be associated with silencing of gene expression in breast carcinomas. Studies with BRCA1 have illustrated the importance of epigenetic silencing in the genesis of sporadic forms of cancer. In 10-15% of women with the nonhereditary form of breast cancer, the BRCA1 gene is hypermethylated and this is accompanied by low to negligible BRCA1 expression. This is the first report of hypermethylation of SOCS genes in primary ovarian and breast cancers. Aberrant methylation was more frequent in ovarian cancers, in which both SOCS1 and SOCS2 were found to be hypermethylated, than in breast tumors. Interestingly, both the SOCS1 and SOCS2 CpG islands were hypermethylated in two ovarian tumors. Silencing of these two genes would be anticipated to profoundly deregulate cytokine signaling in these cells. The lower percentage of SOCS1 hypermethylation observed in breast cancers (9%) contrasts with that observed in hepatocellular carcinomas (65%), and indicates that it is unlikely to be a primary mechanism of gene deregulation in breast tissue. Nevertheless, this frequency is comparable to that of hypermethylation (10-15%) observed for the BRCA1 tumor suppressor gene in breast cancer (Catteau and Morris, 2002). We have shown that SOCS1 and SOCS2 expression could be restored in several ovarian and breast cell lines exhibiting methylation-associated silencing of these genes by treatment with 5-aza-dC. These data provide evidence that aberrant methylation is probably associated with transcriptional silencing of SOCS genes in these cancer cells. While some of the primary cancers appeared not to undergo biallelic methylation, haploinsufficiency following hemimethylation or silencing of the other allele by another mechanism such as histone deacetylation may contribute to oncogenesis in these tumors.
The ability of overexpressed SOCS1 and SOCS2 to suppress anchorage-independent growth of ovarian and breast cancer cells further supports a role for these genes as potential tumor suppressors. Silencing of SOCS genes would be predicted to result in increased cytokine responsiveness. This, in turn, could enhance the growth and/or survival of the epithelia in which this epigenetic event occurs. Thus, hypermethylation and concomitant gene silencing of specific SOCS genes may represent a potentially important mechanism that contributes to ovarian and breast oncogenesis. Figure 4 Growth suppression in ovarian and breast epithelial cells by the SOCS1 and SOCS2 genes. (a) Colony-formation assay using PEO1 ovarian cancer cells. Full-length cDNAs encoding SOCS1, SOCS2 and SOCS3 were cloned into the pEF1a-puro mammalian expression vectors (Lindeman et al., 2001) . PEO1 cells were transfected with linearized expression vectors (10 mg) using LipofectAMINE 2000 (Life Technologies), selected in puromycin for 14 days and the colonies were stained with Giemsa. The bar graph shows the absolute colony number7s.e. in duplicate experiments (b) Suppression of anchorage-independent growth of breast epithelial cells by SOCS1 and SOCS2. Full-length cDNAs encoding SOCS1-3 (Hilton et al., 1998) , each carrying an N-terminal Flagepitope tag, were recloned into a pBabe-retroviral vector containing a puromycin-resistance cassette. MCF-7 EcoR cells at a density of 2 Â 10 6 per 10-cm dish were transduced with retroviruses expressing Flag-tagged SOCS1, SOCS2, SOCS3 or empty vector and selected with 0.5 mg/ml of puromycin for 7-10 days. Transduced MCF-7 cells (2 Â 10 3 ) were then plated in a 0.35% agar overlaying a bottom 0.7% agar layer, for 8 days before staining with 0.5 mg/ml NBT (Sigma). Representative fields were photographed (original mag. Â 1) under phase-contrast microscopy using an Axiocam digital camera. Histogram representing the fold change in colony number in SOCS1, SOCS2 and SOCS3 transductants relative to the vector control. The bars in the graph represent the mean7s.e. of three independent experiments. Immunoprecipitations on whole-cell lysates were carried out as described (Lindeman et al., 2001) 
